(Q36114435)

12 August 2017

Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer (English)

1 reference

12 August 2017

Jonat W

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 September 1998

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

78 Suppl 4

1 reference

12 August 2017

5-8

1 reference

Tamoxifen and endometrial neoplasia

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062750

Gonadotropin-Releasing Hormone Receptors: Characterization, Physiological Regulation, and Relationship to Reproductive Function

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062750

Endocrine effects of goserelin, a new depot luteinising hormone releasing hormone agonist

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062750

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062750

Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062750

Goserelin depot in the treatment of premenopausal advanced breast cancer

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062750

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062750

Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International

23 September 2018

1 reference

12 December 2020

A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer

1 reference

12 December 2020

The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group

1 reference

12 December 2020

Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue

1 reference

12 December 2020

Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.754

1 reference

release_yhvinwlq25extfgpd4gkyoesxi

12 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yhvinwlq25extfgpd4gkyoesxi

24 November 2022

mapped directly with Wikidata item

1 reference

12 August 2017

PubMed publication ID

9741781

1 reference